国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2008年
9期
708-710
,共3页
肝肿瘤%血管内皮生长因子%受体,血管内皮生长因子
肝腫瘤%血管內皮生長因子%受體,血管內皮生長因子
간종류%혈관내피생장인자%수체,혈관내피생장인자
Hepatocellular carcinoma%Vascular endothelial growth factor%Receptors,vascular endo-thelial growth factor
肝癌是富血管性的恶性肿瘤.血管内皮细胞生长因子(VEGF)及其受体(VEGFR)在肿瘤血管生成中发挥了重要作用.而针对VEGF和VEGFR的肝癌治疗药物如索拉非尼、贝伐单抗、干扰素a、PTK787等也日益受到重视.
肝癌是富血管性的噁性腫瘤.血管內皮細胞生長因子(VEGF)及其受體(VEGFR)在腫瘤血管生成中髮揮瞭重要作用.而針對VEGF和VEGFR的肝癌治療藥物如索拉非尼、貝伐單抗、榦擾素a、PTK787等也日益受到重視.
간암시부혈관성적악성종류.혈관내피세포생장인자(VEGF)급기수체(VEGFR)재종류혈관생성중발휘료중요작용.이침대VEGF화VEGFR적간암치료약물여색랍비니、패벌단항、간우소a、PTK787등야일익수도중시.
Hepatocellular carcinoma is hypervascular. Vascular endothelial growth factor(VEGF) and its receptors (VEGFR) play an important role in tumor augiogenesis. The potent drugs targeting VEGF and VEGFR for hepatocellular carcinoma treatment such as sorafenib, bevacizumab, IFNα and PTK787 attract more and more attention.
